Topoisomerase I Inhibitors
"Topoisomerase I Inhibitors" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Compounds that inhibit the activity of DNA TOPOISOMERASE I.
| Descriptor ID |
D059004
|
| MeSH Number(s) |
D27.505.519.389.892.500 D27.505.954.248.794.500
|
| Concept/Terms |
Topoisomerase I Inhibitors- Topoisomerase I Inhibitors
- Inhibitors, Topoisomerase I
- Topoisomerase 1 Inhibitors
- Inhibitors, Topoisomerase 1
- DNA Topoisomerase I Inhibitors
- DNA Type 1 Topoisomerase Inhibitors
|
Below are MeSH descriptors whose meaning is more general than "Topoisomerase I Inhibitors".
Below are MeSH descriptors whose meaning is more specific than "Topoisomerase I Inhibitors".
This graph shows the total number of publications written about "Topoisomerase I Inhibitors" by people in this website by year, and whether "Topoisomerase I Inhibitors" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2014 | 1 | 0 | 1 |
| 2016 | 0 | 1 | 1 |
| 2017 | 1 | 0 | 1 |
| 2019 | 1 | 0 | 1 |
| 2020 | 0 | 1 | 1 |
| 2021 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Topoisomerase I Inhibitors" by people in Profiles.
-
pH-responsive and folate-coated liposomes encapsulating irinotecan as an alternative to improve efficacy of colorectal cancer treatment. Biomed Pharmacother. 2021 Dec; 144:112317.
-
Expression of GM-CSF Is Regulated by Fli-1 Transcription Factor, a Potential Drug Target. J Immunol. 2021 01 01; 206(1):59-66.
-
Gram-negative synergy and mechanism of action of alkynyl bisbenzimidazoles. Sci Rep. 2019 10 02; 9(1):14171.
-
Selective Inhibition of Escherichia coli RNA and DNA Topoisomerase I by Hoechst 33258 Derived Mono- and Bisbenzimidazoles. J Med Chem. 2017 06 22; 60(12):4904-4922.
-
Retinoblastoma Control With Primary Intra-arterial Chemotherapy: Outcomes Before and During the Intravitreal Chemotherapy Era. J Pediatr Ophthalmol Strabismus. 2016 Sep 01; 53(5):275-84.
-
Phase II study of selumetinib (AZD6244, ARRY-142886) plus irinotecan as second-line therapy in patients with K-RAS mutated colorectal cancer. Cancer Chemother Pharmacol. 2015 Jan; 75(1):17-23.